Next Article in Journal
Flavonoids Extracted from Licorice Prevents Colitis-Associated Carcinogenesis in AOM/DSS Mouse Model
Next Article in Special Issue
Fruit Antioxidants during Vinegar Processing: Changes in Content and in Vitro Bio-Accessibility
Previous Article in Journal
Hypoxia Suppresses Spontaneous Mineralization and Osteogenic Differentiation of Mesenchymal Stem Cells via IGFBP3 Up-Regulation
Previous Article in Special Issue
Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease
Open AccessArticle

Effects of Hormone Therapy on Oxidative Stress in Postmenopausal Women with Metabolic Syndrome

Unidad de Investigación en Gerontología, Facultad de Estudios Superiores Zaragoza, Universidad Nacional Autónoma de México, Guelatao No. 66, Col. Ejército de Oriente, Ciudad de México, México CP 09230, Mexico
División de Ginecología y Obstetricia, Hospital General Dr. Gustavo Baz Prada, Instituto de Salud del Estado de México, Av. Bordo de Xochiaca esq. Adolfo López Mateos S/N, Col. Tamaulipas, Nezahualcóyotl, Estado de México, México CP 57300, Mexico
Author to whom correspondence should be addressed.
Academic Editors: Maurizio Battino and Esra Capanoglu
Int. J. Mol. Sci. 2016, 17(9), 1388;
Received: 17 July 2016 / Revised: 11 August 2016 / Accepted: 16 August 2016 / Published: 24 August 2016
(This article belongs to the Special Issue Macro- and Micro-nutrient Antioxidants)
The aim of this study was to determine the effect of oral hormone therapy (HT) on oxidative stress (OS) in postmenopausal women with metabolic syndrome (MetS). A randomized, double blind, placebo-controlled trial was carried out. We formed four groups of 25 women each; healthy (HW) and MetS women (MSW) were assigned to HT (1 mg/day of estradiol valerate plus 5 mg/10 day of medroxiprogesterone) or placebo. We measured plasma lipoperoxides, erythrocyte superoxide dismutase and glutathione peroxidase, total plasma antioxidant status and uric acid, as OS markers. Alternative cut-off values of each parameter were defined and a stress score (SS) ranging from 0 to 7 was used as total OS. MetS was defined according to National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATPIII) criteria. Participants were seen at baseline, 3 and 6 months. After 6 months, MetS decreased in MSW-HT (48%), their triglycerides and high-density lipoprotein cholesterol (HDL-c) improved; in the other groups no difference was found. SS in MSW-HT decreased (3.8 ± 0.3 to 1.7 ± 0.3, p < 0.05) and OS was also reduced (44%), this effect was evident since 3 mo. HW-HT with high OS also decreased (40%). In placebo groups there was no change. Our findings suggest that HT improve lipids and OS associated to MetS in postmenopausal women. View Full-Text
Keywords: oxidative stress; hormone therapy; postmenopause; metabolic syndrome; lipids profile oxidative stress; hormone therapy; postmenopause; metabolic syndrome; lipids profile
Show Figures

Graphical abstract

MDPI and ACS Style

Sánchez-Rodríguez, M.A.; Zacarías-Flores, M.; Castrejón-Delgado, L.; Ruiz-Rodríguez, A.K.; Mendoza-Núñez, V.M. Effects of Hormone Therapy on Oxidative Stress in Postmenopausal Women with Metabolic Syndrome. Int. J. Mol. Sci. 2016, 17, 1388.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop